Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 10, 2014, Pages 2843-2852

  Sawa, Teiji ^a   Ito, Emi ^b   Nguyen, Vinh Huu ^c   Haight, Matthew ^d  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibody; PcrV; Pseudomonas aeruginosa; Type III secretion system; V antigen

Indexed keywords

BACTERIAL ANTIGEN; CYTOTOXIN; IMMUNOGLOBULIN G; MONOCLONAL ANTI-PCRV ANTIBODY; MONOCLONAL ANTIBODY; PSEUDOMONAS AERUGINOSA V ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIGEN V, PSEUDOMONAS; BACTERIAL TOXIN; BACTERIUM ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; KB001 ANTIBODY; PORE FORMING CYTOTOXIC PROTEIN; PSEUDOMONAS VACCINE;

ANTIGEN BINDING; BACTEREMIA; BACTERIAL VIRULENCE; CELL DEATH; CONTROLLED STUDY; CRITICALLY ILL PATIENT; CYSTIC FIBROSIS; DRUG MECHANISM; EUKARYOTIC CELL; FRANCE; HUMAN; IMMUNOTHERAPY; LUNG ALVEOLUS EPITHELIUM; LUNG INJURY; MOLECULAR MECHANICS; MORTALITY; MOUSE; NONHUMAN; PATHOGENESIS; PNEUMONIA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RAT; RESPIRATORY TRACT INFLAMMATION; REVIEW; SALMONELLA; SEPSIS; SEPTIC SHOCK; SHIGELLA; TYPE III SECRETION SYSTEM; UNITED STATES; VACCINATION; VENTILATOR ASSOCIATED PNEUMONIA; YERSINIA; ANIMAL; BACTERIAL SECRETION SYSTEM; IMMUNOLOGY; LUNG; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; PSEUDOMONAS INFECTIONS;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; BACTEREMIA; BACTERIAL SECRETION SYSTEMS; BACTERIAL TOXINS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; LUNG; LUNG INJURY; MICE; PNEUMONIA; PORE FORMING CYTOTOXIC PROTEINS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS VACCINES; SEPSIS;

EID: 84921270557     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/21645515.2014.971641     Document Type: Review

References (58)

1. Parker CM, Kutsogiannis J, Muscedere J, Cook D, Dodek P, Day AG, Heyland DK, Canadian critical care trials G. ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes. J Crit Care 2008; 23:18-26; PMID:18359417; http://dx.doi.org/10.1016/j.jcrc.2008.02.001
2. Bassetti M, Taramasso L, Giacobbe DR, Pelosi P. Management of ventilator-associated pneumonia: epidemiology, diagnosis and antimicrobial therapy. Expert Rev Anti Infect Ther 2012; 10:585-96; PMID:22702322; http://dx.doi.org/10.1586/eri.12.36
3. Grgurich PE, Hudcova J, Lei Y, Sarwar A, Craven DE. Management and prevention of ventilator-associated pneumonia caused by multidrug-resistant pathogens. Expert Rev Respir Med 2012; 6:533-55; PMID:23134248; http://dx.doi.org/10.1586/ers.12.45
4. Barbier F, Andremont A, Wolff M, Bouadma L. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med 2013; 19:216-28; PMID:23524477; http://dx.doi.org/10.1097/MCP.0b013e32835f27be
5. Sawa T, Wiener-Kronish JP. A therapeutic strategy against the shared virulence mechanism utilized by both Yersinia pestis and Pseudomonas aeruginosa. Anesthesiol Clin North Am 2004; 22:591-606, viii-ix; PMID:15325721
6. Wiener-Kronish JP, Frank DW, Sawa T. Mechanisms of lung epithelial cell Injury by acute by Pseudomonas aeruginosa. In: Clark RSB, Carcillo JA, eds. Molecular Biology of Acute Lung Injury Boston, USA: Kluwer Academic Publishers, 2001:149-61; http://dx.doi.org/10.1007/978-1-4615-1427-5-10
7. Sawa T. The molecular mechanism of acute lung injury caused by Pseudomonas aeruginosa : from bacterial pathogenesis to host response. J Intensive Care 2014; 2:10; http://dx.doi.org/10.1186/2052-0492-2-10
8. Hauser AR. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat Rev Microbiol 2009; 7:654-65; PMID:19680249; http://dx.doi.org/10.1038/nrmicro2199
9. Sawa T, Katoh H, Yasumoto H. V-antigen homologs in pathogenic gram-negative bacteria. Microbiol Immunol 2014; 58, 267-85; PMID:24641673; http://dx.doi.org/10.1111/1348-0421.12147
10. Sawa T, Yahr TL, Ohara M, Kurahashi K, Gropper MA, Wiener-Kronish JP, Frank DW. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med 1999; 5:392-8; PMID:10202927
11. Frank DW, Vallis A, Wiener-Kronish JP, Roy-Burman A, Spack EG, Mullaney BP, Megdoud M, Marks JD, Fritz R, Sawa T. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis 2002; 186:64-73; PMID:12089663
12. Baer M, Sawa T, Flynn P, Luehrsen K, Martinez D, Wiener-Kronish JP, Yarranton G, Bebbington C. An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect Immun 2009; 77:1083-90; PMID:19103766; http://dx.doi.org/10.1128/IAI.00815-08
13. Francois B, Luyt CE, Dugard A, Wolff M, Diehl JL, Jaber S, Forel JM, Garot D, Kipnis E, Mebazaa A, et al. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial. Crit Care Med 2012; 40:2320-6; PMID:22622405; http://dx.doi.org/10.1097/CCM.0b013e31825334f6
14. Milla CE, Chmiel JF, Accurso FJ, Vandevanter DR, Konstan MW, Yarranton G, Geller DE, for the KBSG. Anti-PcrV antibody in cystic fibrosis: A novel approach targeting Pseudomonas aeruginosa airway infection. Pediatr Pulmonol 2013; 49:650-8 PMID:24019259; http://dx.doi.org/10.1002/ppul.22890
15. Hauser AR, Cobb E, Bodi M, Mariscal D, Valles J, Engel JN, Rello J. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 2002; 30:521-8; PMID:11990909
16. Kurahashi K, Kajikawa O, Sawa T, Ohara M, Gropper MA, Frank DW, Martin TR, Wiener-Kronish JP. Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia. J Clin Invest 1999; 104:743-50; PMID:15107296
17. Hueck CJ. Type III protein secretion systems in bacterial pathogens of animals and plants. Microbiol Mol Biol Rev 1998; 62:379-433; PMID:9618447
18. Coburn B, Sekirov I, Finlay BB. Type III secretion systems and disease. Clin Microbiol Rev 2007; 20:535-49; PMID:17934073
19. Wong-Beringer A, Wiener-Kronish J, Lynch S, Flanagan J. Comparison of type III secretion system virulence among fluoroquinolone-susceptible and -resistant clinical isolates of Pseudomonas aeruginosa. Clin Microbiol Infect 2008; 14:330-6; PMID:18190571; http://dx.doi.org/10.1111/j.1469-0691.2007.01939.x
20. Agnello M, Wong-Beringer A. Differentiation in quinolone resistance by virulence genotype in Pseudomonas aeruginosa. PLOS one 2012; 7:e42973; PMID:22905192; http://dx.doi.org/10.1371/journal.pone.0042973
21. El-Solh AA, Hattemer A, Hauser AR, Alhajhusain A, Vora H. Clinical outcomes of type III Pseudomonas aeruginosa bacteremia. Crit Care Med 2012; 40:1157-63; PMID:22080633; http://dx.doi.org/10.1097/CCM.0b013e3182377906
22. Howell HA, Logan LK, Hauser AR. Type III secretion of ExoU is critical during early Pseudomonas aeruginosa pneumonia. MBio 2013; 4:e00032-13; PMID:23481600; http://dx.doi.org/10.1128/mBio.00032-13
23. Fleiszig SM, Wiener-Kronish JP, Miyazaki H, Vallas V, Mostov KE, Kanada D, Sawa T, Yen TS, Frank DW. Pseudomonas aeruginosa-mediated cytotoxicity and invasion correlate with distinct genotypes at the loci encoding exoenzyme S. Infect Immun 1997; 65:579-86; PMID:9009316
24. Roy-Burman A, Savel RH, Racine S, Swanson BL, Revadigar NS, Fujimoto J, Sawa T, Frank DW, Wiener-Kronish JP. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 2001; 183:1767-74; PMID:11372029
25. Wiener-Kronish JP, Broaddus VC, Albertine KH, Gropper MA, Matthay MA, Staub NC. Relationship of pleural effusions to increased permeability pulmonary edema in anesthetized sheep. J Clin Invest 1988; 82:1422-9; PMID:3170750
26. Wiener-Kronish JP, Sakuma T, Kudoh I, Pittet JF, Frank D, Dobbs L, Vasil ML, Matthay MA. Alveolar epithelial injury and pleural empyema in acute P. aeruginosa pneumonia in anesthetized rabbits. J Appl Physiol 1993; 75:1661-9; PMID:8282618
27. Kudoh I, Wiener-Kronish JP, Hashimoto S, Pittet JF, Frank D. Exoproduct secretions of Pseudomonas aeruginosa strains influence severity of alveolar epithelial injury. Am J Physiol 1994; 267:L551-6; PMID:7977765
28. Finck-Barbancon V, Goranson J, Zhu L, Sawa T, Wiener-Kronish JP, Fleiszig SM, Wu C, Mende-Mueller L, Frank DW. ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury. Mol Microbiol 1997; 25:547-57; PMID:9302017
29. Ernst EJ, Hashimoto S, Guglielmo J, Sawa T, Pittet JF, Kropp H, Jackson JJ, Wiener-Kronish JP. Effects of antibiotic therapy on Pseudomonas aeruginosa -induced lung injury in a rat model. Antimicrob Agents Chemother 1999; 43:2389-94; PMID:10508012
30. Sato H, Frank DW. Multi-functional characteristics of the Pseudomonas aeruginosa type III needle-tip protein, PcrV; comparison to orthologs in other gram-negative bacteria. Frontiers in Microbiol 2011; 2:142; PMID:21772833; http://dx.doi.org/10.3389/fmicb.2011.00142
31. Brubaker RR. The V antigen of yersiniae: an overview. Contrib Microbiol Immunol 1991; 12:127-33; PMID:1935079
32. Cornelis GR, Wolf-Watz H. The yersinia Yop virulon: a bacterial system for subverting eukaryotic cells. Mol Microbiol 1997; 23:861-7; PMID:9076724
33. Mueller CA, Broz P, Cornelis GR. The type III secretion system tip complex and translocon. Mol Microbiol 2008; 68:1085-95; PMID:18430138; http://dx.doi.org/10.1111/j.1365-2958.2008.06237.x
34. Fields KA, Straley SC. LcrV of Yersinia pestis enters infected eukaryotic cells by a virulence plasmid-independent mechanism. Infect Immun 1999; 67:4801-13; PMID:10456934
35. Pettersson J, Holmstrom A, Hill J, Leary S, Frithz-Lindsten E, von Euler-Matell A, Carlsson E, Titball R, Forsberg A, Wolf-Watz H. The V-antigen of Yersinia is surface exposed before target cell contact and involved in virulence protein translocation. Mol Microbiol 1999; 32:961-76; PMID:10361299
36. Schoehn G, Di Guilmi AM, Lemaire D, Attree I, Weissenhorn W, Dessen A. Oligomerization of type III secretion proteins PopB and PopD precedes pore formation in Pseudomonas. EMBO J 2003; 22:4957-67; PMID:14517235
37. Cornelis GR. The type III secretion injectisome. Nat Rev Microbiol 2006; 4:811-25; PMID:17041629
38. Cornelis GR. The type III secretion injectisome, a complex nanomachine for intracellular 'toxin' delivery. Biol Chem 2010; 391:745-51; PMID:20482311; http://dx.doi.org/10.1515/BC.2010.079
39. Erhardt M, Namba K, Hughes KT. Bacterial nanomachines: the flagellum and type III injectisome. Cold Spring Harb Perspect Biol 2010; 2:a000299; PMID:20926516; http://dx.doi.org/10.1101/cshperspect.a000299
40. Mueller CA, Broz P, Muller SA, Ringler P, Erne-Brand F, Sorg I, Kuhn M, Engel A, Cornelis GR. The V-antigen of Yersinia forms a distinct structure at the tip of injectisome needles. Science 2005; 310:674-6; PMID:16254184
41. Holmstrom A, Olsson J, Cherepanov P, Maier E, Nordfelth R, Pettersson J, Benz R, Wolf-Watz H, Forsberg A. LcrV is a channel size-determining component of the Yop effector translocon of Yersinia. Mol Microbiol 2001; 39:620-32; PMID:11169103
42. Derewenda U, Mateja A, Devedijiev Y, Routzahn KM, Evodokimov AG, Derewenda ZS, Waugh DS. The structure of Yersinia pestis V-antigen, an essential virulence factor and mediator of immunity against plague. Structure 2004; 12:301-6; PMID:11169103
43. Broz P, Mueller CA, Muller SA, Philippsen A, Sorg I, Engel A, Cornelis GR. Function and molecular architecture of the Yersinia injectisome tip complex. Mol Microbiol 2007; 65:1311-20; PMID:17697254
44. Blocker AJ, Deane JE, Veenendaal AK, Roversi P, Hodgkinson JL, Johnson S, Lea SM. What's the point of the type III secretion system needle? Proc Nat Acad of Sci USA 2008; 105:6507-13; PMID:18458349; http://dx.doi.org/10.1073/pnas.0708344105
45. Caroline G, Eric F, Bohn YS, Sylvie E, Attree I. Oligomerization of PcrV and LcrV, protective antigens of Pseudomonas aeruginosa and Yersinia pestis. J Biol Chem 2008; 283:23940-9; PMID:18583342; http://dx.doi.org/10.1074/jbc.M803146200
46. Lee VT, Tam C, Schneewind O. LcrV, a substrate for Yersinia enterocolitica type III secretion, is required for toxin targeting into the cytosol of HeLa cells. J Biol Chem 2000; 275:36869-75; PMID:10930402
47. Dacheux D, Goure J, Chabert J, Usson Y, Attree I. Pore-forming activity of type III system-secreted proteins leads to oncosis of Pseudomonas aeruginosa-infected macrophages. Mol Microbiol 2001; 40:76-85; PMID:11298277
48. Hoiczyk E, Blobel G. Polymerization of a single protein of the pathogen Yersinia enterocolitica into needles punctures eukaryotic cells. Proc Nat Acad of Sci USA 2001; 98:4669-74; PMID:11287645
49. Goure J, Pastor A, Faudry E, Chabert J, Dessen A, Attree I. The V antigen of Pseudomonas aeruginosa is required for assembly of the functional PopB/PopD translocation pore in host cell membranes. Infect Immun 2004; 72:4741-50; PMID:15271936
50. Shime N, Sawa T, Fujimoto J, Faure K, Allmond LR, Karaca T, Swanson BL, Spack EG, Wiener-Kronish JP. Therapeutic administration of anti-PcrV F(ab')(2) in sepsis associated with Pseudomonas aeruginosa. J Immunol 2001; 167:5880-6; PMID:11698464
51. Imamura Y, Yanagihara K, Fukuda Y, Kaneko Y, Seki M, Izumikawa K, Miyazaki Y, Hirakata Y, Sawa T, Wiener-Kronish JP, et al. Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model. Eur Respir J 2007; 29:965-8; PMID:17301098
52. Mikkelsen H, Bond NJ, Skindersoe ME, Givskov M, Lilley KS, Welch M. Biofilms and type III secretion are not mutually exclusive in Pseudomonas aeruginosa. Microbiology. 2009; 155:687-98; PMID:19246740; http://dx.doi.org/10.1099/mic.0.025551-0
53. Neely AN, Holder IA, Wiener-Kronish JP, Sawa T. Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge. Burns 2005; 31:153-8; PMID:15683685
54. Moriyama K, Wiener-Kronish JP, Sawa T. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice. Microbiol Immunol 2009; 53:587-94; PMID:19903258; http://dx.doi.org/10.1111/j.1348-0421.2009.00165.x
55. Faure K, Fujimoto J, Shimabukuro DW, Ajayi T, Shime N, Moriyama K, Spack EG, Wiener-Kronish JP, Sawa T. Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat model. J Immune Based Ther Vaccines 2003; 1:2; PMID:12943554
56. Song Y, Baer M, Srinivasan R, Lima J, Yarranton G, Bebbington C, Lynch SV. PcrV antibody-antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice. Eur J Clin Microbiol Infect Dis 2012; 31:1837-45; PMID:22187351; http://dx.doi.org/10.1007/s10096-011-1509-2
57. Wang Q, Li H, Zhou J, Zhong M, Zhu D, Feng N, Liu F, Bai C, Song Y. PcrV antibody protects multi-drug resistant Pseudomonas aeruginosa induced acute lung injury. Respir Physiol Neurobiol 2014; 193:21-8; PMID:24418353; http://dx.doi.org/10.1016/j.resp2014.01.001
58. Källberg M, Wang H, Wang S, Peng J, Wang Z, Lu H, Xu J. Template-based protein structure modeling using the RaptorX web server. Nature Protocols 2012; 7:1511-22; PMID:22814390; http://dx.doi.org/10.1007/978-1-4939-0366-5-2